ideasIdea
A 'dose evidence' panel in every label: how many doses were tested, and how
A drug's label should say whether its dose was chosen by comparing several doses or simply by finding the most patients could tolerate. Doctors could then know how much room there is to reduce the dose safely.
Labels and public assessment reports include a standard panel: doses tested in humans, whether randomised dose comparison was done, the exposure-response basis, the fraction of pivotal-trial patients who required dose reduction, and any post-approval dose studies. The panel is machine-readable and aggregated publicly.
Hypothesis
Making dose evidence visible will increase sponsor investment in dose optimisation before approval and will increase clinician willingness to use evidence-based dose reductions where the panel shows a flat exposure-response.
Rationale
Clinicians currently cannot tell whether a label dose is optimised or merely tolerated; transparency in other regulated domains (nutrition, energy labelling) changed both producer and consumer behaviour.
What would test it
Introduce the panel; survey oncologists' dose-reduction decisions for agents with and without evidence of dose optimisation, and track dose-optimisation content in submissions over five years.
Maturity
speculative
Who has to act
regulator
Cost to try
Small (under $1M)
Years to first evidence
1
Bottlenecks it attacks
- Wrong doses · Most drug doses were chosen as the highest a person can tolerate, which is often more than they need.
- Knowledge reaches practice too slowly · Knowledge diffusion is slow: it takes years for a proven result to change what most patients receive, and no one can keep up with the literature.